‘The results of CONKO-001 shows that adjuvant treatment with gemcitabine in the dose and use minimal toxicity, does not affect the quality of life, and offers a good, and currently perhaps the best chance for prolonged disease – free survival in patients[ certain types of] resection for pancreatic cancer, the authors conclude.
The study was conducted from July 1988 to December 2004 at 88 oncology centers in Germany and Austria. Patients received chemotherapy with gemcitabine or without chemotherapy . Developed with a median follow-up of 4.5 years, recurrent cancer in 74.3 % in the gemcitabine group and 92 % in the control group. The estimated median disease-free survival was 13.4 months in the gemcitabine group compared with 6.9 months in the control group. Estimated disease-free survival at 3 and 5 years was 23.5 % and 16.5 % in the gemcitabine group and 7.5 % and 5.5 % in the control group. There was no difference in overall survival between the gemcitabine group and the control group..For a gene switch as well when they come ‘unglued, says Califano.. Oral non nuclear DNA presumably more than half all cancers initiate.
The results, from studies from normal and tumor cells derived from human mouth Nose or throat cloth offer more proof that are important regulators for gene activity of occur outside of and the inside DNA in the nucleus is based. – ‘As carcinogen and other mutations vital protein production pathways modify by rewriting of said gene DNA cell code that influence epigenetic changes Generate without change of the code itself , the new studies to say ourselves that such changes not only when methyl occur loyalty.
Research participants were Ian M. Suhail K. Mithani, Michael F. Wenyue Thu, Sheetal Bhan, Andrew Gray, Chunyan Liu, Steven S. Kimberly L. William H. Shahnaz Begum and Mousumi Dhara the Johns Hopkins, and Alexander Vostrov, Ziedulla Abdullaev and Victor Lobanenkov of the NIH.